|46.01||+1.09||+2.43%||Vol 1.13M||1Y Perf -40.50%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-1.01 -2.20%|
|Target Price||75.60||Analyst Rating||Moderate Buy 2.46|
|Potential %||64.31||Finscreener Ranking||★★ 45.90|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★+ 48.24|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★★ 67.36|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||7.16||Earnings Rating||Sell|
|Market Cap||6.34B||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.55|
|EPS Growth Next 5 Years %||11.50|
|Avg. Weekly Volume||802.81K|
|Avg. Monthly Volume||1.11M|
|Avg. Quarterly Volume||1.67M|
Globus Medical Inc. Class A (NYSE: GMED) stock closed at 46.01 per share at the end of the most recent trading day (a 2.43% change compared to the prior day closing price) with a volume of 1.13M shares and market capitalization of 6.34B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 2200 people. Globus Medical Inc. Class A CEO is David M. Demski.
The one-year performance of Globus Medical Inc. Class A stock is -40.5%, while year-to-date (YTD) performance is -38.05%. GMED stock has a five-year performance of -4.72%. Its 52-week range is between 43.385 and 80.04, which gives GMED stock a 52-week price range ratio of 7.16%
Globus Medical Inc. Class A currently has a PE ratio of 47.80, a price-to-book (PB) ratio of 4.09, a price-to-sale (PS) ratio of 7.48, a price to cashflow ratio of 39.10, a PEG ratio of 4.16, a ROA of 8.63%, a ROC of 8.91% and a ROE of 9.64%. The company’s profit margin is 18.72%, its EBITDA margin is 26.90%, and its revenue ttm is $748.35 Million , which makes it $9.67 revenue per share.
Of the last four earnings reports from Globus Medical Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. Globus Medical Inc. Class A’s next earnings report date is -.
The consensus rating of Wall Street analysts for Globus Medical Inc. Class A is Moderate Buy (2.46), with a target price of $75.6, which is +64.31% compared to the current price. The earnings rating for Globus Medical Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Globus Medical Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Globus Medical Inc. Class A has a Neutral technical analysis rating based on Technical Indicators (ADX : 6.04, ATR14 : 1.26, CCI20 : -15.29, Chaikin Money Flow : -0.14, MACD : -0.86, Money Flow Index : 41.05, ROC : 5.07, RSI : 46.72, STOCH (14,3) : 76.61, STOCH RSI : 1.00, UO : 50.97, Williams %R : -23.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Globus Medical Inc. Class A in the last 12-months were: Ann D. Rhoads (Sold 0 shares of value $-94 425 ), Keith Pfeil (Sold 0 shares of value $-1 502 442 ), Keith W. Pfeil (Sold 0 shares of value $-1 502 442 ), Keith W. Pfeil (Sold 29 167 shares of value $2 262 425 ), Lemaitre Dan (Sold 0 shares of value $-199 020 )
Mon, 28 Aug 2023 21:19 GMT Goosehead Insurance to replace NuVasive in S&P 600 at open on 9/1- TipRanks. All rights reserved.
Mon, 17 Jul 2023 02:25 GMT Globus Medical (GMED) Receives a Hold from Truist Financial- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.